Stem cell and functional genomics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Curr Stem Cell Res Ther. 2014;9(5):415-23. doi: 10.2174/1574888x09666140710100143.
About 1 billion cardiomyocytes are lost in heart disease such as myocardial infarction; the regeneration capacity of cardiomyocytes is extremely low and the heart is unable to fix this damage naturally. In the past 20 years, multiple cells, such as skeletal myoblasts, bone marrow-derived cells, cardiac progenitor cells and pluripotent stem cells have been utilized to test the efficacy on heart repair, but these cells show different kinds of drawbacks. Recent studies have revealed that concomitant transplantation of endothelial cells and stem cells can significantly improve the efficacy of cell based heart repair. In this review, we describe the progress on these studies with an emphasis on endothelial cell facilitated stem cell therapy. We also summarize the beneficial mechanisms of endothelial cells in cardiac repair and point out the potential challenges for endothelial cell-facilitated-cell therapy to be adopted for clinical application.
在心脏病(如心肌梗死)中,大约有 10 亿个心肌细胞丢失;心肌细胞的再生能力极低,心脏无法自然修复这种损伤。在过去的 20 年中,已经使用了多种细胞,如骨骼肌成肌细胞、骨髓来源细胞、心脏祖细胞和多能干细胞,来测试心脏修复的效果,但这些细胞表现出不同的缺陷。最近的研究表明,内皮细胞和干细胞的共同移植可以显著提高基于细胞的心脏修复效果。在这篇综述中,我们描述了这些研究的进展,重点介绍了内皮细胞促进的干细胞治疗。我们还总结了内皮细胞在心脏修复中的有益机制,并指出了内皮细胞促进细胞治疗应用于临床所面临的潜在挑战。